Latest news and press releases about Eton Pharmaceuticals, Inc. (ETON): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and...
Price
| Price | $56.35 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 121.18 |
| Price / Book | 33.44 |
| EV / EBITDA | 86.36 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 40.13% |
| Return on Invested Capital | 20.41% |
| Return on Assets | 10.96% |
| Gross Margin | 57.87% |
| Operating Margin | 15.44% |
| Net Margin | 12.02% |
Related companies: ADCT · BCYC · FULC · LCTX · LXRX · MNPR · NMRA
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ETON: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks